European Journal of Pediatrics

, Volume 164, Issue 9, pp 552–558 | Cite as

A literature review on off-label drug use in children

Original Paper

Abstract

The aim was to compare results of studies performed in different settings worldwide and identify common therapeutic areas to allow for focused interventions, because off-label drug use can be a measure of the lack of knowledge concerning paediatric treatments. A secondary objective was to provide a brief review of efforts to date. A literature review of articles on off-label and unlicensed drug use in children involving general prescription samples was performed using Medline and Embase. In all, 30 studies from 1985–2004 were included. Eleven involved paediatric hospital wards, seven neonatal hospital wards, and 12 the community setting. The off-label and unlicensed classification methods varied, making results difficult to compare. In general, off-label/unlicensed prescription rates ranged from 11%–80%, and higher rates were found in younger versus older patients and in the hospital versus community settings. On the paediatric hospital wards, off-label/unlicensed prescriptions ranged from 16%–62% and most often concerned acetaminophen, cisapride, chloral hydrate, and salbutamol. In the neonatal wards, rates ranged from 55%–80% and often involved caffeine. In the community setting, rates ranged from 11%–37% and the most commonly implicated drugs were salbutamol and amoxicillin. Conclusion:A lack of harmonisation between the evidence, the information available to doctors, and its use in clinical practice exists and this is part of the reason off-label therapies are so common. Attempts have been made to improve knowledge concerning paediatric treatments, but more focused interventions are needed, also taking into consideration this lack of harmonisation.

Keywords

Drug Drug labelling Legislation Paediatrics Prescriptions 

Notes

Acknowledgements

Chiara Pandolfini is grateful for a Monzino fellowship.

References

  1. 1.
    American Academy of Pediatrics’ Committee on Drugs (2002) Uses of drugs not described in the package insert (off-label uses). Pediatrics 110: 181–183CrossRefPubMedGoogle Scholar
  2. 2.
    Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C (2000) The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr: 143–147Google Scholar
  3. 3.
    Barr J, Brenner-Zada G, Heiman E, Pareth G, Bulkowstein M, Greenberg R, Berkovitch M (2002) Unlicensed and off-label medication use in a neonatal intensive care unit: a prospective study. Am J Perinatol 19: 67–72CrossRefPubMedGoogle Scholar
  4. 4.
    Bennett WM (2004) Off-label use of approved drugs: therapeutic opportunity and challenges. J Am Soc Nephrol 15: 830–831CrossRefPubMedGoogle Scholar
  5. 5.
    Best Pharmaceuticals for Children Act (2002) Pub. L. 107–109, 107th CongGoogle Scholar
  6. 6.
    Bonati M, Pandolfini C (2004) Is it time for a European formulary of paediatric medicines? Arch Dis Child 89: 890–891CrossRefGoogle Scholar
  7. 7.
    Bonati M, Pandolfini C, Campi R, Clavenna A (2003) Off-label drugs in paediatric primary care (abstract). 14th Congress of the European Society for Ambulatory Paediatrics, Milan, ItalyGoogle Scholar
  8. 8.
    Bonati M, Pandolfini C, Rossi V, Santoro E, Arnau de Bolós JM, Danés Carreras I, Fuentes Camps I, Castel Llobet JM, Jacqz-Aigrain E, Zarrabian S, Choonara I, Sammons H, Steingo J (2004) Launch of a European paediatric clinical trials register. Paediatr Perinat Drug Ther 6: 38–39CrossRefGoogle Scholar
  9. 9.
    Brion F, Nunn AJ, Rieutord A (2003) Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr 92: 486–490Google Scholar
  10. 10.
    Bucheler R, Schwab M, Morike K, Kalchthaler B, Mohr H, Schroder H, Schwoerer P, Gleiter CH (2002) Off-label prescribing to children in primary care in Germany: retrospective cohort study. BMJ 324: 1311–1312CrossRefPubMedGoogle Scholar
  11. 11.
    Burns JP (2003) Research in children. Crit Care Med 31[Suppl 3]: S131–S136Google Scholar
  12. 12.
    Caldwell PH, Murphy SB, Butow PN, Craig JC (2004) Clinical trials in children. Lancet 364: 803–811CrossRefPubMedGoogle Scholar
  13. 13.
    Ceci A, Felisi M, Catapano M, Baiardi P, Cipollina L, Ravera S, Bagnulo S, Reggio S, Rondini G (2002) Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products. Eur J Clin Pharmacol 58: 495–500CrossRefPubMedGoogle Scholar
  14. 14.
    Chalumeau M, Treluyer JM, Salanave B, Assathiany R, Cheron G, Crocheton N, Rougeron C, Mares M, Breart G, Pons G (2000) Off-label and unlicensed drug use among French office based paediatricians. Arch Dis Child 83: 502–505CrossRefPubMedGoogle Scholar
  15. 15.
    Chesney RW, Christensen ML (2004) Changing requirements for evaluation of pharmacologic agents. Pediatrics 113: 1128–1132PubMedGoogle Scholar
  16. 16.
    Choonara I, Conroy S (2002) Unlicensed and off-label drug use in children: implications for safety. Drug Safety 25: 1–5PubMedGoogle Scholar
  17. 17.
    Clarkson A, Ingleby E, Choonara I, Bryan P, Arlett P (2001) A novel scheme for the reporting of adverse drug reactions. Arch Dis Child 84: 337–339CrossRefPubMedGoogle Scholar
  18. 18.
    Committee for Proprietary Medicinal Products, European Agency for the Evaluation of Medicinal Products EMEA (1997) Note for guidance on clinical investigation of medicinal products in children (CPMP/EWP/462/95). EMEA, LondonGoogle Scholar
  19. 19.
    Conroy S (2002) Unlicensed and off-label drug use: issues and recommendations. Paediatr Drugs 4: 353–359PubMedGoogle Scholar
  20. 20.
    Conroy S (2003) Extemporaneous (magistral) preparation of oral medicines for children in European hospitals. Acta Paediatr 92: 408–410Google Scholar
  21. 21.
    Conroy S, McIntyre J, Choonara I (1999) Unlicensed and off-label drug use in neonates. Arch Dis Child Fetal Neonatal Ed 80: F142–F144PubMedGoogle Scholar
  22. 22.
    Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, Knoeppel C, Seyberth H, Pandolfini C, Raffaelli MP, Rocchi F, Bonati M, t’ Jong GW, de Hoog M, van den Anker J (2000) Survey of unlicensed and off-label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320: 79–82CrossRefPubMedGoogle Scholar
  23. 23.
    Craig JS, Henderson CR, Magee FA (2001) The extent of unlicensed and off-label drug use in the paediatric ward of a district general hospital in Northern Ireland. Ir Med J 94: 237–240PubMedGoogle Scholar
  24. 24.
    Department of Health and Human Services, United States Food and Drug Administration (1994) Specific requirements on content and format of labeling for human prescription drugs; revision of the “pediatric use’ subsection in the labeling. Federal Register 59: 64240Google Scholar
  25. 25.
    Dick A, Keady S, Mohamed F, Brayley S, Thomson M, Lloyd BW, Heuschkel R, Afzal NA (2003) Use of unlicensed and off-label medications in paediatric gastroenterology with a review of the commonly used formularies in the UK. Aliment Pharmacol Ther 17: 571–575CrossRefPubMedGoogle Scholar
  26. 26.
    Ekins-Daukes S, Helms PJ, Simpson CR, Taylor MW, McLay JS (2004) Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol 60: 349–353Google Scholar
  27. 27.
    Erickson SH, Bergman JJ, Schneeweiss R, Cherkin DC (1980) The use of drugs for unlabeled indications. JAMA 243: 1543–1546CrossRefPubMedGoogle Scholar
  28. 28.
    European Commission (2002) Better Medicines for Children. Proposed regulatory actions on paediatric medicinal products. Brussels Available at:http://pharmacos.eudra.org/F2/pharmacos/docs/Doc2002/feb/cd_pediatrics_en.pdf
  29. 29.
    European Commission (2004) Proposal for a Regulation of the European Parliament and of the Council on medicinal products for paediatric use. Available at:http://pharmacos.eudra.org/F2/home.html
  30. 30.
    Gavrilov V, Lifshitz M, Levy J, Gorodischer R (2000) Unlicensed and off-label medication use in a general pediatrics ambulatory hospital unit in Israel. Isr Med Assoc J 2: 595–597PubMedGoogle Scholar
  31. 31.
    Gavrilov V, Berkovitch M, Ling G, Brenner-Zadda G, Sofer S, Lifshitz M, Gorodischer R (2001) Unapproved prescriptions in two paediatric intensive care units in Israel (abstract). Paediatr Perinatal Drug Ther 4: 176Google Scholar
  32. 32.
    Gill AM, Leach HJ, Hughes J, Barker C, Nunn AJ, Choonara I (1995) Adverse drug reactions in a paediatric intensive care unit. Acta Paediatr 84: 438–441Google Scholar
  33. 33.
    Hames A, Wynne HA (2001) Unlicensed and off-label drug use in elderly people. Age Ageing 30: 530–531CrossRefGoogle Scholar
  34. 34.
    Hanna K, Poulin-Costello M, Preston M, Maresky N (2003) Intravenous immune globulin use in Canada. Can J Clin Pharmacol 10: 11–16PubMedGoogle Scholar
  35. 35.
    Herxheimer A (2004) Open access to industry’s clinically relevant data. BMJ 329: 64–65CrossRefPubMedGoogle Scholar
  36. 36.
    Horen B, Montastruc JL, Lapeyre-Mestre M (2002) Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 54: 665–670CrossRefPubMedGoogle Scholar
  37. 37.
    How best to serve children (2000) Lancet 356: 1619CrossRefPubMedGoogle Scholar
  38. 38.
    Impicciatore P, Choonara I (1999) Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br J Clin Pharmacol 48: 15–18CrossRefPubMedGoogle Scholar
  39. 39.
    International Conference on Harmonization (ICH) (2000) E11 Clinical Investigation of Medicinal Products in the Paediatric Population. Available at:http://www.fda.gov/cber/gdlns/ichclinped.pdf
  40. 40.
    Khaled AL, Ahmad F, Brogan T, Fearnley J, Graham J, MacLeod S, McCormick J (2003) Prescription medicine use by one million Canadian children. Paediatr Child Health 8[Suppl A]: 1A–56AGoogle Scholar
  41. 41.
    Kleist P (2002) Authorities recognize a need to encourage pediatric drug development. Applied Clinical Trials 11: 408Google Scholar
  42. 42.
    Lifshitz M, Gavrilov V, Gorodischer R (1999) Use of unlicensed and off-label drugs in hospitalized children. Harefuah 137: 532–534PubMedGoogle Scholar
  43. 43.
    Lifshitz M, Gavrilov V, Grossman Z, Binsthok M, Hornik D, Rosemblum H, Chemni S, Alkrinawi S, Miron D, Gorodischer R (2002) Unapproved prescription practices in primary pediatric clinics in Israel: a prospective analysis. Curr Ther Res Clin Exp 63: 830–837CrossRefGoogle Scholar
  44. 44.
    Martin RM, Wilton LV, Mann RD, Steventon P, Hilton SR (1998) Unlicensed and off-label drug use for paediatric patients. General practitioners prescribe SSRIs to children off-label. BMJ 317: 204Google Scholar
  45. 45.
    Matsui DM, Jardine ME, Steer E, Cukernik V, Rieder MJ (2003) Where physicians look for information on drug prescribing for children. Paediatr Child Health 8: 219–221Google Scholar
  46. 46.
    McIntyre J, Conroy S, Avery A, Corns H, Choonara I (2000) Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 83: 498–501CrossRefPubMedGoogle Scholar
  47. 47.
    McKinney RE Jr (2003) Congress, the FDA, and the fair development of new medications for children. Pediatrics 112: 669–670CrossRefPubMedGoogle Scholar
  48. 48.
    McKinzie JP, Wright SW, Wrenn KD (1997) Pediatric drug therapy in the emergency department: does it meet FDA-approved prescribing guidelines? Am J Emerg Med 15: 118–121CrossRefPubMedGoogle Scholar
  49. 49.
    Ministero della Salute. Guida all’uso dei farmaci per i bambini (2003) Istituto Poligrafico e Zecca dello Stato, RomaGoogle Scholar
  50. 50.
    Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, Brune K, Hinz B (2004) The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Safety 27: 1059–1067PubMedGoogle Scholar
  51. 51.
    Nunn AJ (2003) Making medicines that children can take. Arch Dis Child 88: 369–371CrossRefPubMedGoogle Scholar
  52. 52.
    O’Donnell CPF, Stone RJ, Morley CJ (2002) Unlicensed and off-label drug use widespread in Australian NICUs. Pediatrics 110: e52CrossRefPubMedGoogle Scholar
  53. 53.
    Pandolfini C, Bonati M (2003) Off-label drug use in children in Europe: a major health issue. Pharm Dev Regul 1: 133–143Google Scholar
  54. 54.
    Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M, Cattaneo MG, Cornelli P, Mirabile L, Raffaelli MP, Sonzogni W, Taddei G, Tellarini L, Bagarolo N, Cordiano L, Pedrini A, Rampazzo R, Zorzi C, Chiarelli F, Mohn A, De Donno V, Favetta S, Pietraru C, Poggio L, Vivani P, Monina G, Primi A, Coppini A, Di Pietro P, Gusmano R, Mastrangioli A, Panetta E, Perfumo F, Rossi R, Amato C, Giaretto G, Marone I, Rocatti L, Serravalle P, D’Andrea N, Lardo G, Marchetti F, Mencoboni MC, Taccardi R, Ferrarese A, Joppi R, Temporin G, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M (2002) Off-label use of drugs in Italy: a prospective, observational and multicentre study. Acta Paediatr 91:339–347Google Scholar
  55. 55.
    Pandolfini C, Bonati M, Giozani M, Raffaelli MP, Rossi R, Serra G, Joppi R, Temporin G (2003) Off-label and unlicensed drug use in neonatal wards of three different Italian hospitals (abstract). Paed Perinat Drug Ther 5: 169Google Scholar
  56. 56.
    Pediatric Research Equity Act (2003) Pub. L. No. 108155 (S.650)Google Scholar
  57. 57.
    Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients (1998) Federal Register 63: 66632Google Scholar
  58. 58.
    Riordan FA (2000) Use of unlabelled and off license drugs in children. Use of unlicensed drugs may be recommended in guidelines. BMJ 320: 1210CrossRefGoogle Scholar
  59. 59.
    Roberts R, Rodriguez W, Murphy D, Crescenzi T (2003) Pediatric drug labeling: improving the safety and efficacy of pediatric therapies. JAMA 290: 905–911CrossRefPubMedGoogle Scholar
  60. 60.
    Royal College of Paediatrics and Child Health (1999) Medicines for Children. British Medical Association, LondonGoogle Scholar
  61. 61.
    Schirm E, Tobi H, de Jong-van den Berg LTW (2003) Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 111: 291–295CrossRefPubMedGoogle Scholar
  62. 62.
    Serradel J, Patwell JT (1991) Unlabeled drug use patterns in a contemporary outpatient setting. J Pharmacoepidemiol 2: 19–43Google Scholar
  63. 63.
    Serreau R, Le Heuzey MF, Gilbert A, Mouren MC, Jacqz-Aigrain E (2004) Unlicensed and off-label use of psychotropic medications in French children: a prospective study. Paediatr Perinat Drug Ther 6: 14–19CrossRefGoogle Scholar
  64. 64.
    Steinbrook R (2002) Testing medications in children. N Engl J Med 347: 1462–1470CrossRefPubMedGoogle Scholar
  65. 65.
    Steinbrook R (2004) Public registration of clinical trials. N Engl J Med 351: 315–317CrossRefPubMedGoogle Scholar
  66. 66.
    ’t Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, Van Den Anker JN (2001) A survey of the use of off-label and unlicensed drugs in a Dutch children’s hospital. Pediatrics 108: 1089–1093Google Scholar
  67. 67.
    ’t Jong GW, Eland IA, de Hoog M, Sturkenboom MC, Van Den Anker JN, Stricker BH (2002) Unlicensed and off-label prescription of systemic anti-infective agents to children. Paediatr Perinat Drug Ther 5: 68–74Google Scholar
  68. 68.
    ’t Jong GW, Eland IA, Sturkenboom MC, Van Den Anker JN, Stricker BH (2002) Unlicensed and off-label prescription of drugs to children: population based cohort study. BMJ 324: 1313–1314Google Scholar
  69. 69.
    ’t Jong GW, Stricker BH, Choonara I, Van Den Anker JN (2002) Lack of effect of the European guidance on clinical investigation of medicines in children. Acta Paediatr 91: 1233–1238Google Scholar
  70. 70.
    ’t Jong GW, Eland IA, Sturkenboom MC, Van Den Anker JN, Stricker BH (2003) Determinants for drug prescribing to children below the minimum licensed age. Eur J Clin Pharmacol 58: 701–705Google Scholar
  71. 71.
    Tan E, Cranswick NE, Rayner CR, Chapman CB (2003) Dosing information for paediatric patients: are they really “therapeutic orphans”? Med J Aust 179: 195–198PubMedGoogle Scholar
  72. 72.
    Thompson DF, Heflin NR (1987) Frequency and appropriateness of drug prescribing for unlabeled uses in pediatric patients. Am J Hosp Pharm 44: 792–794PubMedGoogle Scholar
  73. 73.
    Thouvenel C, Geny MS, Demirdjian S, Vassal G (2002) Statutory pediatric information available for anticancer drugs: inventory and proposals. Arch Pediatr 9: 685–693CrossRefPubMedGoogle Scholar
  74. 74.
    Treluyer JM, Berger JF, Pons G (2001) Use of “off-label” and unlicensed drugs in neonatal and paediatric intensive care units in France. (abstract). Paediatr Perinatal Drug Ther 4: 176Google Scholar
  75. 75.
    Turner S (1999) Unregistered and off-label drug use in paediatric inpatients. Aust J Hosp Pharm 29: 265–268Google Scholar
  76. 76.
    Turner S, Gill A, Nunn T, Hewitt B, Choonara I (1996) Use of “off-label” and unlicensed drugs in paediatric intensive care unit. Lancet 347: 549–550CrossRefGoogle Scholar
  77. 77.
    Turner S, Longworth A, Nunn AJ, Choonara I (1998) Unlicensed and off-label drug use in paediatric wards: prospective study. BMJ 316: 343–345PubMedGoogle Scholar
  78. 78.
    Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88: 965–968Google Scholar
  79. 79.
    Ufer M, Panagiotidis G, Kvist EE, Rane A, Bergman U (2002) Lack of an association between the frequency of off-label prescribing and the risk of adverse drug reactions in paediatric outpatients. 8th Biennial Congress of the European Society for Developmental Perinatal and Paediatric Pharmacology, Liège, Belgium 25–28 OctoberGoogle Scholar
  80. 80.
    Ufer M, Rane A, Karlsson A, Kimland E, Bergman U (2003) Widespread off-label prescribing of topical but not systemic drugs for 350,000 paediatric outpatients in Stockholm. Eur J Clin Pharmacol 58: 779–783PubMedGoogle Scholar
  81. 81.
    Ufer M, Kimland E, Bergman U (2004) Adverse drug reactions and off-label prescribing for paediatric outpatients: a one-year survey of spontaneous reports in Sweden. Pharmacoepidemiol Drug Safety 13: 147–152CrossRefGoogle Scholar
  82. 82.
    United States Food and Drug Administration Modernization Act (1997) Pub L No. 105-115, 105th CongGoogle Scholar
  83. 83.
    Wilton LV, Pearce G, Mann RD (1999) The use of newly marketed drugs in children and adolescents prescribed in general practice. Pharmacoepidemiol Drug Safety 8: S37–S45CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  1. 1.Laboratory for Mother and Child Health“Mario Negri” Institute for Pharmacological ResearchMilan Italy

Personalised recommendations